BCM
CHRS icon

BlueCrest Capital Management’s Coherus Oncology CHRS Stock Holding History

BlueCrest Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,628
Closed -$246K – 932
2017
Q1 		$246K Buy
+11,628
New +$286K 0.01% 573

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlueCrest Capital Management's CHRS Position: Q2 2017 in Review

BlueCrest Capital Management sold out of Coherus Oncology (CHRS) in Q2 2017, closing a stake of 11,628 shares — an estimated $246K sold.

BlueCrest Capital Management first reported a position in CHRS in Q1 2017 and held it in 1 quarter. The position peaked at $246K in Q1 2017. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

  • BlueCrest Capital Management reported no remaining Coherus Oncology position as of Q2 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,628 Coherus Oncology shares in Q2 2017, an estimated $246K.
  • BlueCrest Capital Management first reported a position in Coherus Oncology in Q1 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Coherus Oncology position peaked at $246K in Q1 2017.
  • 106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.